Specifically, we show that later generation N-terminal HSP90 inhibitors, such as luminespib and ganetespib, display strong anti-tumor activity with effects on cell viability, cell proliferation, cellular migration, and to a lesser extent on apoptosis. Here, HSP90AA1 is linked to neoplasm.